Executive SummaryThe endless cycle of mergers is no answer to the basic growth problems of now oversized pharmaceutical companies, in part because little real restructuring goes on with the acquirer, who needs it as much as the target. But one set of acquirers we haven't heard from could accomplish a lot of the necessary reforms: the large IT companies who could apply not only their technologies to improve marketing and business practices in the drug industry, but their management philosophies.
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.